TY - JOUR
T1 - Symptomatic Bradycardia Due to Alectinib in a Patient with Advanced Stage of NSCLC
AU - Pitoyo, Ceva Wicaksono
AU - Rumende, Cleopas Martin
AU - Wiraputri, Anindita Kartika
AU - Audita, Fatira Ratri
N1 - Publisher Copyright:
© 2022, Indonesian Society of Internal Medicine. All rights reserved.
PY - 2022/4/1
Y1 - 2022/4/1
N2 - Alectinib is one of the targeted therapies commonly given to patients with advanced non-small cell lung cancer (NSCLC) with mutations in the ALK gene. The most common adverse effects of alectinib are fatigue, constipation, edema, myalgia and anemia. Meanwhile, bradycardia was reported as a very common adverse effect, but generally asymptomatic, unlike the reported patient in this case report. This case report's purpose is to increase awareness of the possibility of adverse effects due to alectinib administration that require immediate intervention in order to improve the quality of life and patient survival, especially in patients with advanced NSCLC.
AB - Alectinib is one of the targeted therapies commonly given to patients with advanced non-small cell lung cancer (NSCLC) with mutations in the ALK gene. The most common adverse effects of alectinib are fatigue, constipation, edema, myalgia and anemia. Meanwhile, bradycardia was reported as a very common adverse effect, but generally asymptomatic, unlike the reported patient in this case report. This case report's purpose is to increase awareness of the possibility of adverse effects due to alectinib administration that require immediate intervention in order to improve the quality of life and patient survival, especially in patients with advanced NSCLC.
KW - alectinib
KW - bradycardia
KW - NSCLC
UR - http://www.scopus.com/inward/record.url?scp=85133737974&partnerID=8YFLogxK
M3 - Article
C2 - 35818649
AN - SCOPUS:85133737974
SN - 0125-9326
VL - 54
SP - 303
EP - 306
JO - Acta medica Indonesiana
JF - Acta medica Indonesiana
IS - 2
ER -
